A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
NCT ID: NCT02133625
Last Updated: 2016-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
28 participants
INTERVENTIONAL
2011-08-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
NCT05023486
Phase I Study in Patients With Solid Tumours
NCT00496028
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
NCT00420524
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
NCT02129205
Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
NCT01304303
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* In Part II of the trial, an MTD Expansion Cohort may be utilized to further characterize the safety profile and pharmacodynamics of the drug. Patients in the MTD Expansion Cohort will receive carboplatin alone on cycle 1, day 1. Over days 15-21 of the cycle pioglitazone will be administered alone. On cycle 2, day 1, both carboplatin and pioglitazone will be administered.
Cycle 2 and onward are 21-day cycles, with pioglitazone administered once daily and carboplatin administered once every 3 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pioglitazone and Carboplatin
MTD Determination
* Pioglitazone: 45 mg Once Daily by mouth,Cycle 1Days 1-28; Subsequent cycles: Days 1-21
* Carboplatin:6 AUC IV 60 minute infusion (or per institutional policy) Cycle 1: Day 8; Subsequent cycles: Day 1
carboplatin
pioglitazone
MTD Expansion Carboplatin and Pioglitazone
MTD Expansion:
* Carboplatin alone on cycle 1, day 1.
* Pioglitazone Over days 15-21 of the cycle pioglitazone will be administered alone.
* On cycle 2, day 1, both carboplatin and pioglitazone will be administered. Cycle 2 and onward are 21-day cycles, with pioglitazone administered once daily and carboplatin administered once every 3 weeks
carboplatin
pioglitazone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
carboplatin
pioglitazone
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* During Part I of the trial (MTD determining phase), measurable or evaluable disease is acceptable. For Part II of the trial (expanded cohort) only, participants must have measurable disease by RECIST criteria version 1.1.
* Participants enrolled in Part II of the trial (expanded cohort) must have disease that is amenable to biopsy with reasonable safety and also be willing to undergo at least two serial tumor biopsies for correlative biomarker investigation as defined in Section 8.2.2.
* Any number of prior therapies are permitted. Prior carboplatin is allowed. Patients who have documented allergy to carboplatin may receive carboplatin with desensitization.
* Age ≥18 years old.
* ECOG performance status ≤ 1 (Appendix A).
* Participants must have normal organ and marrow function as defined below:
* Absolute neutrophil count ≥1,500/L
* Hematocrit ≥ 27
* Platelets ≥100,000/L
* Total bilirubin within normal institutional limits
* AST (SGOT)/ALT (SGPT)≤ 2.5 X institutional upper limit of normal
* Creatinine within normal institutional limits or creatinine clearance ≥ 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
* Able to swallow oral medication.
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
* Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
* Subjects who have been treated with standard chemotherapy or molecularly targeted agents within the past 3 weeks prior to trial first drug administration.
* Subjects who were receiving experimental therapies must wait 3 weeks from their last dose prior to enrolling. Subjects treated with nitrosoureas or mitomycin C cannot be enrolled until 6 weeks has elapsed since their last treatment.
* Extensive prior radiotherapy on more than 25% of the bone marrow, or prior bone marrow/stem cell transplantation. Prior radiation for local disease management is allowed if last fraction was completed at least 4 weeks prior to trial entry.
* Subjects who have undergone a major surgical procedure within the 6 weeks prior to trial entry.
* History of untreated central nervous system (CNS) metastases. Subjects with a history of prior treated brain metastasis are eligible provided that 1 month following treatment they are stable by CT scan without evidence of cerebral edema, and have no requirements for corticosteroids.
* Diabetic patients who are currently requiring oral hypoglycemic agents or insulin therapy.
* Patients who are currently receiving rosiglitazone or pioglitazone, or who have received dosing with any other agent known to be a PPAR agonist within 3 months prior to study entry.
* Left ventricular ejection fraction ≤ 50% on ECHO or MUGA
* Uncontrolled concomitant illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Pregnant or nursing women.
* Known HIV positivity, active hepatitis C, or active hepatitis B.
* Patients with ≥ CTCAE Grade 2 peripheral neuropathy.
* Subjects with a known history of gastrointestinal disorder (such as partial esophageal, gastric, small or large bowel obstruction), surgery or malabsorption that could potentially impact the swallowing or the absorption of the study drug.
* Patients taking CYP2C8 inhibitors and inducers (rifampin, gemfibrozil, trimethoprim, montelukast, and quercetin) are excluded from the trial.
* Other significant disease that in the Investigator's opinion would exclude the subject from the trial.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dana-Farber Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
James Cleary, MD, PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Cleary, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Dana Farber Cancer Instiute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-096
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.